NCT03404466View on ClinicalTrials.gov

To Explore the Safety and Efficacy of Hypidone Hydrochloride Tablets in Treatment of Patients With MDD

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 24, 2018

Primary Completion Date

July 10, 2018

Study Completion Date

July 17, 2018

Conditions

Major Depressive Disorder

Interventions

DRUG

Hypidone Hydrochloride tablets

Hypidone Hydrochloride tablets 10 or 20mg/day Study drug is to be given orally, twice daily, for 6 weeks

Trial Locations (1)

200030

Shanghai mental health center, Shanghai

All Listed Sponsors

lead

Zhejiang Huahai Pharmaceutical Co., Ltd.

INDUSTRY

NCT03404466 - To Explore the Safety and Efficacy of Hypidone Hydrochloride Tablets in Treatment of Patients With MDD | Biotech Hunter | Biotech Hunter